CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Abiraterone acetate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01940276
NCT01940276Phase 2Completed
CompareCT.gov

A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer

Duke University·interventional·Posted Sep 12, 2013·Updated Dec 9, 2020

In Brief

A Phase 2 clinical trial evaluating Abiraterone acetate and Prednisone for Prostate Cancer. Completed, enrolled 100 participants across 14 sites.

Detailed Summary

The primary goal is to prospectively estimate the median radiographic PFS of African American and Caucasian men with mCRPC to abiraterone acetate and prednisone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 12, 2013
Enrollment StartOct 1, 2013
Primary CompletionOct 8, 2019
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 12.8 years ago

Interventions

Abiraterone acetatedrug

Prednisonedrug